A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Cells competing for a place in a germinal center confront a tough admissions process. Germinal centers, which form following exposure to a pathogen or vaccine, serve as a kind of immune system training academy, assisting B cells in refining their response to the threat.
A novel genome assembly tool that has been created by researchers could lead to the creation of fresh antibiotics for the bacterial infections that cause tuberculosis and other diseases.
Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have designed a small fluorescent protein that emits and absorbs light that penetrates deep into biological tissue.
The Crimean Congo Hemorrhagic Fever Virus can be prevented by therapeutically relevant human monoclonal antibodies, according to research led by the University of California, Riverside.
Researchers at Chalmers University of Technology in Sweden have developed synthetic DNA that uses artificial intelligence to control the production of proteins in cells.
Rutgers researchers have devised a new way to prevent viral infections: a live-attenuated, replication-defective DNA virus vaccine that utilizes the substance centanamycin to create an altered virus for vaccine development.
A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.
The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.
According to a recent study led by Andrés Finzi, a professor at the Université de Montréal and researcher at the CHUM Research Centre, the type of virus used as a model to study the effectiveness of non-neutralizing antibodies against the virus that causes AIDS, has a crucial role to play.
The immune system’s capacity to remember defeated disease-causing germs and avoid recurrent infections is still poorly understood, but a new study published in Science Immunology fills in some gaps.
The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.
Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.
Vaccines function by effectively producing immune cells that live for a long time, frequently for decades. These immune cells form a protective barrier that prevents or reduces re-infection, as well as a memory that enables one to identify an old invader, such as a virus, and eliminate it before it causes disease.
When tested in a lab setting using human cells, a panel of experimental monoclonal antibodies (mAbs) that target various Epstein-Barr virus (EBV) sites prevented infection.
Scientists from the University of California, Los Angeles (UCLA) have discovered a Zika vaccine technology that is very safe and effective in preclinical mouse models.
According to scientists from the Georgia State University’s Institute for Biomedical Sciences, producing a mutation that impedes the way the bacterial pathogen Neisseria gonorrhoeae transmits gonorrhea might provide a novel means to prevent and treat the disease.
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.